CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

NICE has rejected a drug from CSL Behring for treating genetic emphysema in draft guidance, saying that it would cost a £8 million per QALY.

CSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients with rare diseases manage their conditions.

Get the latest Carlisle Companies Incorporated (CSL) stock news and headlines to help you in your trading and investing decisions.